Full Press Release Details
Eyenovia Initiates Phase III MicroStat
Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
Topline results for Phase III MicroStat
program expected H1 2019
New York, NY - November 26, 2018
- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first
of two Phase III trials (MIST-1 and MIST-2) of the Company's MicroStat program for pharmacologic mydriasis, or dilation of
the pupil for an eye exam. The studies will investigate the safety and efficacy of the Company's first-in-class fixed-combination
phenylephrine 2.5% - tropicamide 1% ophthalmic solution, administered as a micro-dose using the Optejet dispenser. Pharmacologic
mydriasis is an important part of an estimated 80 million office-based comprehensive and diabetic eye exams performed each year
in the United States and is essential for the standard dilated retinal fundoscopic examination.
"With the enrollment of the first
patient in the first pivotal trial of MicroStat for pharmacologic mydriasis, Eyenovia officially transitions into a Phase III company,"
commented Dr. Sean Ianchulev, Eyenovia's
Chief Executive Officer and Chief Medical Officer. "We believe that our fixed-combination of phenylephrine and tropicamide
has the potential to significantly improve both the patient experience and physician workflow during eye exams. We look forward
to announcing topline results from both trials in our Phase III MicroStat program in the first half of 2019."
The two Phase III trials are randomized,
double-blind, multicenter-superiority studies, which will each enroll approximately 65 participants in the United States. In the
MIST-1 study, both eyes of the participants will be treated on separate days with Eyenovia's proprietary fixed combination
mydriatic solution and each of the component solutions. In the MIST-2 study, participants will receive Eyenovia's fixed combination
mydriatic solution and a placebo on separate days. All treatments will be administered using the Optejet dispenser. The primary
endpoint for both studies is the mean change in baseline pupil diameter at 35 minutes after administration of study treatment.
Eyenovia, Inc. (NASDAQ: EYEN) is a specialty
biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and
formulation platform for microdosing. Eyenovia's pipeline is currently focused on the late-stage development of microdosed
medications for myopia progression, glaucoma, mydriasis and other eye diseases.
Forward Looking Statements
Except for historical information, all
of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking
statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions
or any other statements relating to our future activities or other future events or conditions. These statements are based on current
expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore,
actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking
statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements
could be affected by risks and uncertainties related to, among other things: risks involved in clinical trials, including, but
not limited to, the initiation, timing, progress and results of such trials; the timing and our ability to submit applications
for, obtain and maintain regulatory approvals for, our product candidates; our ability to develop and implement commercialization,
marketing and manufacturing capabilities and strategies; the potential advantages of our product candidates; the rate and degree
of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for
our product candidates; intellectual property risks; the impact of government laws and regulations; and our competitive position.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable
securities laws, we do not undertake any obligation to update any forward-looking statements.
Caution: New Drug Limited by Federal (United
States) law to investigational use.
Chief Financial Officer
Tram Bui / Alexander Lobo
Phone: 646-536-7035/7037